Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, September 27 '25)

Image
By G.M.

 


    Am J Med

  1. WAHID L, Kwon T, Kreuziger LB, Kasthuri RS, et al
    Extended Thromboprophylaxis in Patients Hospitalized with COVID-19 at Time of Discharge is Not Associated with Improvement in Quality of Life.
    Am J Med. 2025;138:1464-1468.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  2. ZHANG L, Li Y, Ye K, Wang P, et al
    Article I. metformin affects H1N1-induced apoptosis in lung epithelial cells by the miR-130a-5p-regulated PI3K/AKT signaling pathway.
    Biochem Biophys Res Commun. 2025;782:152526.
    PubMed         Abstract available


    J Gen Virol

  3. HA Y, Lee YH, Jo HS, Kwon TW, et al
    Susceptibility of different mouse strains to SARS-CoV-2 spike receptor-binding domain protein-induced lung inflammation: a comparative study.
    J Gen Virol. 2025;106.
    PubMed         Abstract available


    J Infect Dis

  4. GAILLET A, Layese R, Fourati S, Celante H, et al
    Clinical Phenotypes and Outcomes Associated With Respiratory Syncytial Virus Infection in Critically Ill Patients: A Retrospective Multicenter Cohort Study in Greater Paris Area Hospitals, 2017-2023.
    J Infect Dis. 2025;232:679-690.
    PubMed         Abstract available

  5. LI K, Bont LJ, Weinberger DM, Pitzer VE, et al
    Relating In Vivo Respiratory Syncytial Virus Infection Kinetics to Host Infectiousness in Different Age Groups.
    J Infect Dis. 2025;232:691-699.
    PubMed         Abstract available

  6. LI K, Pitzer VE, Weinberger DM
    Exploring RSV Transmission Patterns in Different Age Groups in the United States.
    J Infect Dis. 2025;232:700-708.
    PubMed         Abstract available

  7. DOSS CR, Osborn MJ, Stark S, Rhein J, et al
    Wastewater Measures of SARS-CoV-2 Accurately Predict Frequency of Symptomatic Infections in the Community.
    J Infect Dis. 2025;232:e459-e465.
    PubMed         Abstract available

  8. HAMILTON F, Butler-Laporte G, Davey Smith G
    Mendelian Randomization and Infection: Pitfalls and Promises.
    J Infect Dis. 2025;232:525-533.
    PubMed         Abstract available

  9. WANG C, Yuan HY, Lau EHY, Cowling BJ, et al
    Impact of Population Immunity and Public Health Measures on the Transmission of Omicron Subvariants BA.2 and BA.5 in Hong Kong.
    J Infect Dis. 2025;232:e476-e485.
    PubMed         Abstract available

  10. KNOX JJ, Lee I, Blumberg EA, Rosenfeld AM, et al
    B-Cell Subset Representation Predicts SARS-CoV-2 Vaccine Response in Solid Organ Transplant Recipients.
    J Infect Dis. 2025 Jun 3:jiaf250. doi: 10.1093.
    PubMed         Abstract available

  11. LIM SY, Lee J, Kwon JS, Chang E, et al
    Disparate kinetics of viable virus shedding in immunocompromised patients: SARS-CoV-2 versus influenza virus - a prospective real-world cohort study.
    J Infect Dis. 2025 Sep 15:jiaf479. doi: 10.1093.
    PubMed         Abstract available

  12. ALEMNJI G, Sangthong A, Espy N, Bartee M, et al
    PEPFAR Laboratory Implementation Strategy as a Component of PEPFAR's 5-Year Strategy.
    J Infect Dis. 2025;232.
    PubMed         Abstract available

  13. OKOYE M, Okoi C, Espy N, Mba N, et al
    Leveraging PEPFAR- and Global Fund-Supported Laboratory Network for Integrated Disease Testing: Lessons From Integrated HIV, Tuberculosis, and COVID-19 Testing in Nigeria.
    J Infect Dis. 2025;232.
    PubMed         Abstract available


    J Virol

  14. MA Y, Ye C, Khalil AM, Mahmoud SH, et al
    A luminescent attenuated SARS-CoV-2 for the identification and validation of drug-resistant mutants.
    J Virol. 2025 Aug 7:e0082125. doi: 10.1128/jvi.00821.
    PubMed         Abstract available

  15. KARIMI A, Lieber CM, Sakamoto K, Plemper RK, et al
    SARS-CoV-2 causes chronic lung inflammation and impaired respiratory capacity in aged Roborovski dwarf hamsters.
    J Virol. 2025 Aug 11:e0075525. doi: 10.1128/jvi.00755.
    PubMed         Abstract available

  16. BATY JJ, Drozdick AK, Pfeiffer JK
    Pseudomonas aeruginosa rhamnolipids stabilize human rhinovirus 14 virions.
    J Virol. 2025;99:e0093125.
    PubMed         Abstract available

  17. HU J, Zheng H, Ran W, Wang X, et al
    Mucosal vaccination with long-form TSLP induces migratory cDC1-mediated adaptive immunity against SARS-CoV-2 infection.
    J Virol. 2025 Aug 19:e0123125. doi: 10.1128/jvi.01231.
    PubMed         Abstract available

  18. EL ZOWALATY ME, Taylor LJ, Son Y, Lee H, et al
    Discovery, phylogenetic, and comparative genomic analysis of novel avian gammacoronaviruses identified in feral pigeons (Columba livia domestica).
    J Virol. 2025 Aug 20:e0111225. doi: 10.1128/jvi.01112.
    PubMed         Abstract available

  19. ZHANG H, Deng X, Dai R, Fu J, et al
    Inadequate immune response to inactivated COVID-19 vaccine among older people living with HIV: a prospective cohort study.
    J Virol. 2025 Aug 21:e0068825. doi: 10.1128/jvi.00688.
    PubMed         Abstract available

  20. CHI X, Liang X, Vaddadi K, Zhang X, et al
    SARS-CoV-2 Nsp15 endoribonuclease subverts host defenses to enhance viral fitness in lung cells.
    J Virol. 2025 Aug 21:e0117525. doi: 10.1128/jvi.01175.
    PubMed         Abstract available

  21. HU Z, Tian S, Zhou Y, Wang Y, et al
    Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses.
    J Virol. 2025 Aug 26:e0090325. doi: 10.1128/jvi.00903.
    PubMed         Abstract available

  22. VERMA A, Kamboj H, Kumar G, Khandelwal N, et al
    TGF-beta inhibitor SB431542 suppresses SARS-CoV-2 replication through multistep inhibition.
    J Virol. 2025 Aug 29:e0052925. doi: 10.1128/jvi.00529.
    PubMed         Abstract available

  23. GRACIE NP, Aggarwal A, Luo R, Spicer M, et al
    An RGD motif on SARS-CoV-2 Spike induces TGF-beta signaling and downregulates interferon.
    J Virol. 2025 Sep 4:e0043525. doi: 10.1128/jvi.00435.
    PubMed         Abstract available

  24. JANZEN GM, Inderski BT, Chang J, Arendsee ZW, et al
    Sources and sinks of influenza A virus genomic diversity in swine from 2009 to 2022 in the United States.
    J Virol. 2025;99:e0054125.
    PubMed         Abstract available

  25. ZHU B, Fung K, Feng HH, Beatty JA, et al
    The hemagglutinin proteins of clades 1 and 2.3.4.4b H5N1 highly pathogenic avian influenza viruses exhibit comparable attachment patterns to avian and mammalian tissues.
    J Virol. 2025 Sep 23:e0097625. doi: 10.1128/jvi.00976.
    PubMed         Abstract available


    PLoS Comput Biol

  26. LIM D, Ko KT, Hong H, Lee H, et al
    A history-dependent approach for accurate initial condition estimation in epidemic models.
    PLoS Comput Biol. 2025;21:e1013438.
    PubMed         Abstract available

  27. HODGSON D, Hay J, Jarju S, Jobe D, et al
    serojump: A Bayesian tool for inferring infection timing and antibody kinetics from longitudinal serological data.
    PLoS Comput Biol. 2025;21:e1013467.
    PubMed         Abstract available


    PLoS Med

  28. PREISS A, Bhatia A, Aragon LV, Baratta JM, et al
    Effect of Paxlovid treatment during acute COVID-19 on Long COVID onset: An EHR-based target trial emulation from the N3C and RECOVER consortia.
    PLoS Med. 2025;22:e1004711.
    PubMed         Abstract available


    PLoS One

  29. SALDIVAR L, Rajabi T, Li W, Lopa S, et al
    Recurrent venous thromboembolism and clot distribution in COVID-19 infection: A review by variant type.
    PLoS One. 2025;20:e0331283.
    PubMed         Abstract available

  30. SAW HW, Kapteyn A
    Personality traits, panel tenure, survey topic, and context as predictors of survey nonresponse patterns in high-frequency online longitudinal surveys.
    PLoS One. 2025;20:e0332902.
    PubMed         Abstract available

  31. BASHORUN AO, Kotei L, Jallow AF, Jawla O, et al
    Human papillomavirus, sexually transmitted infections, and antimicrobial resistance in West Africa: Estimating population burden and understanding exposures to accelerate vaccine impact and drive new interventions: The PHASE survey protocol.
    PLoS One. 2025;20:e0332842.
    PubMed         Abstract available

  32. SHIMIZU IS, Freire SF, Sousa MLA, Ferreira JC, et al
    Knowledge, attitudes, and practice about protective ventilation among physical therapists.
    PLoS One. 2025;20:e0331949.
    PubMed         Abstract available

  33. LU W, Liu Q, Li H
    Confidence, animal spirits, and the macroeconomy in China: Based on mixed-frequency data models.
    PLoS One. 2025;20:e0332909.
    PubMed         Abstract available

  34. WANG J, Liu Y, Li N, Zhu Y, et al
    Hand hygiene after the COVID-19 pandemic: Is it still at a high level?
    PLoS One. 2025;20:e0332634.
    PubMed         Abstract available

  35. EDU-QUANSAH DA, Bandoh DA, Edu-Quansah EP, Appiah AB, et al
    Evaluation of the performance of the Influenza-like Illness (ILI) surveillance system in the Okai Koi North District, Greater Accra Region, 2022.
    PLoS One. 2025;20:e0332334.
    PubMed         Abstract available

  36. BOEVER C, Zech E, Arcand L, Verdon C, et al
    What does it mean to have experienced the death of a relative in a context of social and funeral restrictions? Lessons from the pandemic for bereavement research and clinical practice.
    PLoS One. 2025;20:e0331946.
    PubMed         Abstract available

  37. SWANSON B, Bishop-Royse J, Keshavarzian A, Balk R, et al
    Examination of unique volatile organic compound signatures in nasopharyngeal test swab viral transport media using an electronic nose.
    PLoS One. 2025;20:e0332399.
    PubMed         Abstract available

  38. REITERMAN M, Chin AI, Bang H
    Adverse outcomes post-COVID-19 hospitalization among ESRD patients: A retrospective cohort study in 5 California university medical centers.
    PLoS One. 2025;20:e0332203.
    PubMed         Abstract available

  39. PAYNE LA, Edelman A, Darney BG, Benhar E, et al
    Brief report: Older adolescents and young adults may be at higher risk for changes to menstrual cycle length with COVID-19 vaccination.
    PLoS One. 2025;20:e0331346.
    PubMed         Abstract available

  40. POLISHCHUK V, Kostinov capital EM, Cyrillic, Ryzhov capital A, Cyrillic, Dagil Y, et al
    Immunogenicity of one dose and two doses of adjuvanted influenza vaccine in lung transplant candidates.
    PLoS One. 2025;20:e0332346.
    PubMed         Abstract available

  41. PEREZ-MORALES AM, Jimenez-Juarez RN, Morales-Rios OM, Reyes-Lopez A, et al
    Antibacterial consumption before, during, and after the COVID-19 pandemic in a tertiary care pediatric hospital in Mexico.
    PLoS One. 2025;20:e0329220.
    PubMed         Abstract available

  42. KAYA MG, Karaman K
    Clinical parameters associated with mortality in elderly patients with COVID-19.
    PLoS One. 2025;20:e0332800.
    PubMed         Abstract available

  43. MONGE M, Hurtado R, Infante J
    Time trends and persistence of the return difference between growth and value investment strategies.
    PLoS One. 2025;20:e0332690.
    PubMed         Abstract available

  44. WANG Y, Gao YD, Jiang CH, Xi Y, et al
    Characterisation of a novel chicken-derived H3N3 avian influenza virus detected in China in 2023: Pathogenicity and immunogenicity.
    PLoS One. 2025;20:e0332213.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  45. YOSHIDA A, Uekusa Y, Suzuki T, Bauer M, et al
    Enhanced visualization of influenza A virus entry into living cells using virus-view atomic force microscopy.
    Proc Natl Acad Sci U S A. 2025;122:e2500660122.
    PubMed         Abstract available


    Vaccine

  46. SCHERM MJ, Holzl R, Gonzalez-Dominguez I, Hjorth R, et al
    Assessment of critical bioprocess parameters for broadly cross-reactive chimeric hemagglutinin influenza virus vaccines.
    Vaccine. 2025;64:127671.
    PubMed         Abstract available

  47. HARIT D, Sawant S, Spreng RL, Gurley S, et al
    Qualification of a reporter virus microneutralization assay for evaluation of influenza specific antibodies in human clinical trials.
    Vaccine. 2025;64:127699.
    PubMed         Abstract available

  48. HUI S, He R, Li H, Li Y, et al
    Revealing dynamic transcriptomic and immune cell signatures underlying heterogeneous responses to influenza vaccination.
    Vaccine. 2025;64:127777.
    PubMed         Abstract available

  49. PALACHE B, Fyyaz H, Thomson D, Taylor B, et al
    The IFPMA IVS seasonal influenza vaccine dose distribution survey 2022-2023: evidence of the need for committed national investment in and uptake of seasonal influenza vaccination.
    Vaccine. 2025;64:127747.
    PubMed         Abstract available

  50. SARTORI AL, Buffarini R, Bertoldi AD, da Silveira MF, et al
    Association between maternal influenza vaccination and childhood vaccination among participants of the 2015 Pelotas (Brazil) birth cohort.
    Vaccine. 2025;64:127761.
    PubMed         Abstract available


    Virus Res

  51. SHI X, Wang J, Li C, Du S, et al
    Single amino acid substitution at position 614 in SARS-CoV-2 Spike Protein alters viral assembly and infectivity.
    Virus Res. 2025;360:199624.
    PubMed         Abstract available

  52. GONG T, Zhang X, Lin H, Li J, et al
    Mutation profiling, evolution analysis, molecular dynamics simulation, and functional characterization of Omicron sub-strains.
    Virus Res. 2025;360:199626.
    PubMed         Abstract available

  53. RAMASAMY S, Bustamante F, LaBella LC, Cole SD, et al
    Spillover of SARS-CoV-2 to domestic dogs in COVID-19-positive households: A one health surveillance study.
    Virus Res. 2025;360:199629.
    PubMed         Abstract available

  54. CHAVOIX C, Massin P, Briand FX, Louboutin K, et al
    Identification of H1N2 influenza viruses in turkeys after spillover from swine and in vitro characterization.
    Virus Res. 2025 Sep 21:199634. doi: 10.1016/j.virusres.2025.199634.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »